Business
The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.
FEATURED STORIES
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
At Harbinger, Hahn will oversee the development of the Bio-AI diagnostics platform dubbed HarbingerHx, in hopes of detecting cancer in a patient before it is visible or symptomatic.
The counterclaim by an alleged victim of MIT professor David Sabatini said she was coerced into sex and that Sabatini’s laboratory had a “toxic and sexually charged” environment.
The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company’s future growth.
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
Surrozen’s ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.
NanoMosaic plans to use the funds raised to continue building its commercial infrastructure, developing its applications, and advancing diagnostic collaborative development programs.